Paul K Paik

Paul K Paik

UNVERIFIED PROFILE

Are you Paul K Paik?   Register this Author

Register author
Paul K Paik

Paul K Paik

Publications by authors named "Paul K Paik"

Are you Paul K Paik?   Register this Author

35Publications

1226Reads

35Profile Views

New Treatment Options in Advanced Squamous Cell Lung Cancer.

Am Soc Clin Oncol Educ Book 2019 Jan 17;39:e198-e206. Epub 2019 May 17.

5 The University of Texas MD Anderson Cancer Center, Houston, TX.

View Article

Download full-text PDF

Source
https://ascopubs.org/doi/10.1200/EDBK_237829
Publisher Site
http://dx.doi.org/10.1200/EDBK_237829DOI Listing
January 2019

Liquid biopsy guided precision therapy for lung cancers.

J Thorac Dis 2018 Nov;10(Suppl 33):S4173-S4175

Thoracic Oncology Services, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY, USA.

View Article

Download full-text PDF

Source
http://jtd.amegroups.com/article/view/25283/19042
Publisher Site
http://dx.doi.org/10.21037/jtd.2018.11.02DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6297506PMC
November 2018

Relevance of genetic alterations in squamous and small cell lung cancer.

Ann Transl Med 2017 Sep;5(18):373

Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/atm.2017.06.72DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5635252PMC
September 2017

OncoKB: A Precision Oncology Knowledge Base.

JCO Precis Oncol 2017 Jul 16;2017. Epub 2017 May 16.

, Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA; , Gastrointestinal Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; , Gynecologic Medical Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; , Breast Medicine Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Weill Cornell Medical College, New York, NY USA; , Breast Medicine Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; , Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center , New York, NY, USA, Weill Cornell Medical College, New York, NY USA; , Head and Neck Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; , , Department of Hematology and Oncology, Quest Diagnostics Nichols Institute, 33608 Ortega Highway, San Juan Capistrano, CA, 92675, USA; , Department of R&D and Bioinformatics, Quest Diagnostics Nichols Institute, 33608 Ortega Highway, San Juan Capistrano, CA, 92675, USA; , Head and Neck Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Weill Cornell Medical College, New York, NY USA; , Melanoma and Immunotherapeutics Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Weill Cornell Medical College, New York, NY USA; , Gynecologic Medical Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; , Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Sarcoma Medical Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA, Weill Cornell Medical College, New York, NY USA; Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Weill Cornell Medical College, New York, NY USA; , Developmental Therapeutics, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Sarcoma Medical Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA, Weill Cornell Medical College, New York, NY USA; , Gastrointestinal Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Weill Cornell Medical College, New York, NY USA; , Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY, USA; , Brain Tumor Center, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY, USA; , Department of Oncology and Internal Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Weill Cornell Medical College, New York, NY USA; , Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, USA; , Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA , Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; , Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; , Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; , Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; , Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Developmental Therapeutics, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; , Breast Medicine Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Developmental Therapeutics, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Weill Cornell Medical College, New York, NY USA; , Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Weill Cornell Medical College, New York, NY USA; , Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

View Article

Download full-text PDF

Source
https://www.researchgate.net/profile/Debyani_Chakravarty/pub
Web Search
http://ascopubs.org/doi/10.1200/PO.17.00011
Publisher Site
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5586540PMC
http://dx.doi.org/10.1200/PO.17.00011DOI Listing
July 2017

Successful Use of Afatinib After Erlotinib-induced Pneumonitis in a Patient With Epidermal Growth Factor Receptor-mutant Lung Cancer.

Clin Lung Cancer 2017 01 26;18(1):e81-e83. Epub 2016 Oct 26.

Department of Medicine, Weill Cornell Medical College, New York, NY; Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2016.10.001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5490243PMC
January 2017

Missing the mark in FGFR1-amplified squamous cell cancer of the lung.

Cancer 2016 10 17;122(19):2938-40. Epub 2016 Jun 17.

Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/cncr.30131
Publisher Site
http://dx.doi.org/10.1002/cncr.30131DOI Listing
October 2016

Something Old, Something New, Something Borrowed, Something Fused: Novel EGFR Rearrangements in Lung Adenocarcinomas.

Authors:
Paul K Paik

Cancer Discov 2016 06;6(6):574-5

Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. Weill Cornell Medical College, New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-16-0478DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4894533PMC
June 2016

Autoimmune Bullous Skin Disorders with Immune Checkpoint Inhibitors Targeting PD-1 and PD-L1.

Cancer Immunol Res 2016 05 29;4(5):383-9. Epub 2016 Feb 29.

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. Weill Cornell Medical College, New York, New York. Department of Dermatology, Memorial Sloan Kettering Cancer Center, New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2326-6066.CIR-15-0123DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241697PMC
May 2016

Beyond adenocarcinoma: current treatments and future directions for squamous, small cell, and rare lung cancer histologies.

Am Soc Clin Oncol Educ Book 2015 :147-62

From The University of Texas Southwestern Medical Center, Dallas, TX; Memorial Sloan Kettering Cancer Center, New York, NY; Case Western Reserve University, Cleveland, OH.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.14694/EdBook_AM.2015.35.147DOI Listing
February 2016

Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping.

Cancer Discov 2015 Aug 13;5(8):842-9. Epub 2015 May 13.

Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York. Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-14-1467DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4658654PMC
August 2015

Next-Generation Sequencing of Stage IV Squamous Cell Lung Cancers Reveals an Association of PI3K Aberrations and Evidence of Clonal Heterogeneity in Patients with Brain Metastases.

Cancer Discov 2015 Jun 30;5(6):610-21. Epub 2015 Apr 30.

Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. Weill Cornell Medical College, New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-14-1129DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4643059PMC
June 2015

Clinical characteristics and course of 63 patients with BRAF mutant lung cancers.

J Thorac Oncol 2014 Nov;9(11):1669-74

Departments of *Medicine, Thoracic Oncology Service, Division of Solid Tumor Oncology, †Epidemiology and Biostatistics, and ‡Pathology, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0000000000000344DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4251710PMC
November 2014

Risk of hemoptysis in patients with resected squamous cell and other high-risk lung cancers treated with adjuvant bevacizumab.

Cancer Chemother Pharmacol 2013 Aug 28;72(2):453-61. Epub 2013 Jun 28.

Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, Weill Cornell Medical School, 300 East 66th Street, New York, NY 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-013-2219-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4653739PMC
August 2013

Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinomas.

Cancer 2013 Jan 18;119(2):356-62. Epub 2012 Jul 18.

Feinberg School of Medicine, Northwestern University, The Robert H. Lurie Comprehensive Cancer Center, Chicago, Illinois 60611, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.27730DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3966555PMC
January 2013

Driver mutations determine survival in smokers and never-smokers with stage IIIB/IV lung adenocarcinomas.

Cancer 2012 Dec 17;118(23):5840-7. Epub 2012 May 17.

Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.27637DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3424296PMC
December 2012

Response to erlotinib in patients with EGFR mutant advanced non-small cell lung cancers with a squamous or squamous-like component.

Mol Cancer Ther 2012 Nov 14;11(11):2535-40. Epub 2012 Aug 14.

Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, 300 East 66 Street, New York, NY 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-12-0163DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3640858PMC
November 2012

Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma-rationale for comprehensive mutation profiling.

Mol Cancer Ther 2012 Feb 1;11(2):485-91. Epub 2011 Dec 1.

Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan-Kettering Cancer Center, Weill Cornell Medical College, New York, New York, USA.

View Article

Download full-text PDF

Source
http://mct.aacrjournals.org/cgi/doi/10.1158/1535-7163.MCT-11
Publisher Site
http://dx.doi.org/10.1158/1535-7163.MCT-11-0692DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3593239PMC
February 2012

Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations.

Clin Cancer Res 2012 Feb 6;18(4):1167-76. Epub 2012 Jan 6.

Department of Pathology, Thoracic Oncology Service, Department of Medicine, and Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, NY 10065, USA.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-11-2109DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3487403PMC
February 2012

A phase 2 study of weekly albumin-bound paclitaxel (Abraxane®) given as a two-hour infusion.

Cancer Chemother Pharmacol 2011 Nov 3;68(5):1331-7. Epub 2011 Apr 3.

Department of Medicine, Thoracic Oncology Service, Division of Solid Tumor Oncology, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, H1011, New York, NY 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-011-1621-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3581346PMC
November 2011

Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations.

J Clin Oncol 2011 May 11;29(15):2046-51. Epub 2011 Apr 11.

Memorial Sloan-Kettering Cancer Center and Weill Medical College of Cornell University, New York, NY 10065, USA.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2010.33.1280
Publisher Site
http://dx.doi.org/10.1200/JCO.2010.33.1280DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3107760PMC
May 2011

A phase I study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in solid tumor malignancies.

Cancer Chemother Pharmacol 2010 Nov 18;66(6):1079-85. Epub 2010 Feb 18.

Thoracic Oncology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-010-1265-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2945625PMC
November 2010

Histone deacetylase inhibitors in malignant pleural mesothelioma: preclinical rationale and clinical trials.

J Thorac Oncol 2010 Feb;5(2):275-9

Thoracic Oncology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0b013e3181c5e366DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4052955PMC
February 2010

IFN-gamma suppresses IL-10 production and synergizes with TLR2 by regulating GSK3 and CREB/AP-1 proteins.

Immunity 2006 May;24(5):563-74

Arthritis and Tissue Degeneration Program, Hospital for Special Surgery, Weill Graduate School of Medical Sciences of Cornell University, New York, New York 10021, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.immuni.2006.02.014DOI Listing
May 2006